Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact

Submit a comment

Biomarkers of endothelial activation/dysfunction distinguish subgroups of Ugandan patients with sepsis and differing mortality risks
Danielle V. Clark, … , William J. Moss, Shevin T. Jacob
Danielle V. Clark, … , William J. Moss, Shevin T. Jacob
Published April 23, 2019
Citation Information: JCI Insight. 2019;4(10):e127623. https://doi.org/10.1172/jci.insight.127623.
View: Text | PDF
Clinical Medicine Clinical trials Infectious disease

Biomarkers of endothelial activation/dysfunction distinguish subgroups of Ugandan patients with sepsis and differing mortality risks

  • Text
  • PDF
Abstract

BACKGROUND Sepsis is a complex clinical syndrome with substantial heterogeneity. We sought to identify patterns of serum biomarkers of endothelial activation and dysfunction in individuals with sepsis and evaluate subgroup-specific differences in mortality.METHODS Adult patients with sepsis (n = 426) were consecutively recruited from 2 hospitals in Uganda. Clinical information was collected, and serum concentrations of 11 biomarkers involved in the endothelial response to infection were measured in samples from 315 patients. Latent variable models were fit to evaluate whether the endothelial response to sepsis consists of one unified biologic process or multiple processes and to identify subgroups of patients with distinct host-response profiles. Differences in survival at day 28 were evaluated using Kaplan-Meier survival curves.RESULTS We identified 3 patient subgroups characterized by unique host endothelial response profiles. Patients fitting profile 2 had significantly worse survival (log-rank P < 0.001). Four latent factors (factors 1–4) were identified, each potentially representing distinct biologic processes for the endothelial response to sepsis: factor 1 (CHI3L1, sTREM1, sFLT1), factor 2 (ANGPT1, PF4, VEGF), factor 3 (CXCL10, vWF, sICAM1), and factor 4 (ANGPT2, sTEK).CONCLUSION Patient profiles based on patterns of circulating biomarkers of endothelial responses may provide a clinically meaningful way to categorize patients into homogeneous subgroups and may identify patients with a high risk of mortality. Profile 2 may represent dysfunction of the endothelial response to infection.FUNDING Primary funding: Investigator-Initiated Award provided by Pfizer Inc. Additional support: Canadian Institutes of Health Research Foundation grant (FDN-148439) and the Canada Research Chair program.

Authors

Danielle V. Clark, Patrick Banura, Karen Bandeen-Roche, W. Conrad Liles, Kevin C. Kain, W. Michael Scheld, William J. Moss, Shevin T. Jacob

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts